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HUMAN PAPILLOMAVIRUS VACCINE UPTAKE IN THE UNITED STATES: 
EXPLORING ALTERNATIVE VACCINATION SITES TO INCREASE UPTAKE 
HANNA VICTORIA PETERSON 
ABSTRACT 
Human Papillomavirus is one of the most common sexually transmitted infections (STI) 
worldwide and is associated with more than 70% of invasive cervical cancer (ICC) cases.  
Vaccines against high-risk HPV infections have been developed: Gardasail, a 
quadrivalent vaccine protecting against HPV 16, 18, 6, and 11, and Cervarix for types 16 
and 18 only. Although these vaccines have proven to be safe and effective in preventing 
HPV, vaccine coverage in the US remains much lower than other developed countries 
including Australia, the UK, and Canada. This thesis focuses on the implications of low 
HPV vaccine uptake and strategies to increase coverage in the US, specifically alternative 
venues for vaccine provision.  Results from the literature search showed that common 
barriers to HPV vaccine uptake include lack of knowledge about HPV and the vaccines 
and lack of physician recommendation.  With regards to alternative vaccination provision 
sites, the literature search showed the most evidence for mass vaccination in schools, 
particularly in Australia where government funded school-based vaccination programs 
have increased the national HPV vaccine coverage to 70%. Further, the literature search 
showed that pharmacies are another promising alternative venue for HPV vaccine 
administration because of their high accessibility and convenience.  
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 1 
INTRODUCTION 
 
Human Papillomavirus: Biological foundation 
 Papillomaviruses are double-stranded, 8000 base pair DNA viruses which are 
non-enveloped and icosahedral in shape (Chelimo, Wouldes, Cameron, Elwood, 2012).  
These viruses are epitheliotropic and specifically infect the stratified squamous epithelia 
of the skin, oral cavity and anogenital tract. There are over 100 types of known 
Papillomaviruses, 40 of which affect the anogenital tract (Chelimo et al., 2012). Dr. 
Harald Zur Hausen isolated Human papillomavirus (HPV) type 16 from genital warts in 
1983, and HPV 18 one year later, causing a major shift in the scientific theory of genital 
tract carcinogenesis, the causative agent for which was previously thought to be infection 
with Herpes Simplex Virus (Erickson, Alvarez, Huh, 2013).  
 It is now known that HPV 16 and 18 cause between 60-80% of cervical cancers 
worldwide (Erickson et al., 2013). Additionally, HPV 16 and 18 are prevalent in 64-91% 
of vaginal cancers, 82-100% severe vaginal intraepithelial neoplasia cases, 88-94% of 
anal cancers, 60-90% of penile and vulvar cancers, and a substantial percentage of 
incident head and neck squamous cell carcinomas (Chelimo et al., 2012). Although types 
16 and 18 are most commonly associated with malignancies, they are not the only types 
with the potential for carcinogenicity (see Table1 for a complete list of HPV 
classification). Additionally, low risk HPV 6 and 11 cause genital warts.  
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Table 1. HPV classification. This table gives a list of HPV types organized by their 
carcinogenic potential: 12 types are carcinogenic and 8 or more may be carcinogenic. 
HPV 16 and 18 are the most high-risk types of infection.  Low risk HPV types 6 and 11 
are of note as they cause genital warts (taken from Erickson, Alvarez, Huh, 2013). 
 
There are types of HPV that infect non-mucosal skin surfaces, however HPV 
types that infect mucosal skin surfaces are contracted almost exclusively via sexual 
transmission with the cervix being the most common site of transmission (Erickson et al., 
2013). There are approximately 500,000 new cases of cervical cancer a year with a 
mortality of nearly 250,000. Since HPV causes anywhere from 60-80% of cervical 
cancers, it has come to the forefront of sexually transmitted disease and vaccine research 
over the past twenty years.  
 
Infection and Malignancy 
 According to Oh and Weiderpass (2013) infection is one of the main methods of 
carcinogenesis. Some common carcinogenic infections include Epstein Barr Virus, 
Hepatitis B and C, Kaposi’s sarcoma herpes virus, HIV, and HPV. In 2008, there were 
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12.7 million new cancer cases worldwide, 2 million (16%) of which were due to 
infectious agents (Oh and Weiderpass, 2013). Interestingly, the majority of new cancer 
cases associated with infectious agents occurred in underdeveloped countries, making up 
22.9% of new cancer diagnoses in underdeveloped countries versus 7.4% of new cancer 
diagnoses in more developed countries (Oh and Weiderpass, 2013).  
Of the 500,000 new cases of cervical disease annually and 250,000 deaths, over 
80% occur underdeveloped countries (Oh and Weiderpass, 2013).  These astounding 
statistics make HPV stand out amongst other infections that cause malignancies; almost 
all cervical cancers are positive for HPV DNA, making the risk of HPV for cervical 
cancer greater than smoking for lung cancer and Hepatitis B for liver cancer (Franco and 
Harper, 2005). 
 
How does HPV infection cause cervical cancer? 
HPV infects the cervix of its hosts through micro abrasions in the stratified 
squamous epithelium of the transformation zone, part of the cervix where columnar and 
squamous epithelia coexist as a result of squamous metaplasia that occurs during puberty 
(Kumar, Abbas, and Aster, 2012). During intercourse, the cervix suffers small tears, 
allowing HPV to enter the basement membrane of the epithelium where it “relaxes” its 
conformation, is endocytosed, and trafficked to the nucleus where its genome persists as 
an episome (Carter, Ding, and Rose, 2011). These cells actively replicate HPV viral DNA 
as they migrate through the epithelium to the outermost layer where the viral DNA is 
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then packaged into infectious particles (virions) that are shed with the sloughed off skin 
cells and released to infect other cells (Erickson et al., 2013). 
 
Figure 1. Mechanism of HPV infection. A schematic representation of infection with 
HPV in the stratified squamous epithelium of the cervix and the pathological changes 
associated with the progression of cervical intraepithelial neoplasia (adapted from 
Crosbie, Einstein, Franceschi and Kitchener, 2013).  
 
 
Although infection with HPV is necessary for the development of cervical 
intraepithelial neoplasia and invasive cervical carcinomas, it is not in itself sufficient to 
cause malignancy. Persistence, integration, and transformation of the virus must occur for 
the development of cervical cancer (Carter et al., 2011). Three known oncogenes are 
responsible for these processes: E2, E6, and E7. HPV integrates itself into the host 
genome through deregulation of the E2 gene, which linearizes the circular HPV viral 
DNA and allows it to integrate into the host genome (Carter et al., 2011). This integration 
then deregulates E6 and E7 which degrade p53 and inactivate the retinoblastoma (Rb) 
tumor suppressor gene, respectively. The deregulation and disruption of these oncogenes 
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causes cell immortality and unregulated cell proliferation, both hallmarks of cancer 
progression (Carter et al., 2011). 
Cervical Intraepithelial Neoplasia (CIN): Pathology and Staging 
While high risk strains HPV 16 and 18 are known to cause several different types 
of cancer, cervical cancer affects the most individuals worldwide. In order to fully 
understand the risks associated with HPV infection, general knowledge of cervical 
intraepithelial neoplasia (CIN) and invasive cervical carcinoma (ICC) is essential. CIN is 
a pre-cancerous epithelial change that is sub-classified into three “stages” of dysplasia: 
low grade (I), moderate (II), and severe (III) dysplasia (Kumar et al., 2012). Newer 
classification divides these changes into two stages: low grade squamous intraepithelial 
lesions (LSIL; formerly CIN I) and high-grade squamous intraepithelial lesions (HSIL; 
formerly CIN II and III). These changes were made to reflect the likelihood of regression 
versus persistence of cytological abnormalities (or HPV infection); 60% of LSIL’s 
regress and 30% persist, whereas 30% of HSIL’s regress and 60% persist, putting women 
with HSIL’s at higher risk for developing ICC (Kumar et al., 2012).  
Figure 2 shows the pathological and cytological progression from normal cervical 
epithelium to CIN III. CIN I is classified by dysplasia in the lower third of the epithelium 
with some changes in epithelial structure in the upper two thirds; CIN II is characterized 
by the spread of dysplasia into the middle third of the epithelium, delayed maturation of 
cells, and mitoses above the basal layer (the active layer of the epithelium); CIN III is a 
more drastic change with almost no stratification in cell maturation, variation in cell size, 
and abnormal mitoses in all layers (Kumar et al., 2012). Cytologically, there is an 
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increase in nucleus to cytoplasm ratio suggestive of malignant activity (Kumar et al., 
2012). 
             
 
Figure 2.  Pathological and cytological progression of cervical intraepithelial 
neoplasia. This figure shows pathology and cytology slides of the progression of CIN 
from normal cervical tissue to CIN III (adapted from Kumar et al., 2012). 
 
 
CIN is detected primarily by the Papanicolau (Pap) screening test, the most 
commonly used cancer-screening test to date. This simple test involves scraping cells 
from the transformation zone for microscopic examination and, since its advent, the 
incidence of invasive tumors in the US has been reduced to 12,000 per year with a 
mortality of 4,000, so that it is no longer one of the top ten causes of death amongst 
women in the US (Kumar et al., 2012). An abnormal Pap smear is followed up with 
colposcopy which reveals lesions on the cervix (Kumar et al., 2012) LSIL are followed 
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carefully for several years, whereas HSIL’s are followed up with removal of 
transformation zone using LEEP (loop electrosurgical excision procedure) or cold knife 
cone biopsy ) (“WHO | Treatment of cervical intraepithelial neoplasia 2–3 and 
adenocarcinoma in situ,” n.d.). 
As a result of screening programs in the US, invasive cervical cancers (ICC’s) are 
now mostly seen in women who have not had a recent Pap test or have not followed up 
after and abnormal screening test. Unlike CIN, ICC is symptomatic; women present with 
vaginal bleeding, leukorrhea, painful coitus, and dysuria. Treatment is very invasive and 
may include radical hysterectomy and lymph node dissection, chemotherapy, and 
radiation therapy. Mortality correlates with tumor stage and most women die from a local 
invasion or renal failure (Kumar et al., 2012). While screening programs have been 
successful in developed countries, they are costly. Screening, follow up and treatment of 
cervical cancer in the US costs an estimated $6 billion a year (Carter et al., 2011), which 
acts as a major barrier for bringing such programs to underdeveloped countries where 
most ICC incidences and mortalities occur. 
 
Risk Factors for HPV Infection 
“Most women in the world will be infected with HPV at some time during their lifetime” 
(Bosch). 
 Based on results from a 2008 World Health Organization (WHO) meta-analysis 
“at any given point in time, 10.4% of the women worldwide are positive for HPV DNA 
in the cervix.” (Bosch et al.). The distribution of HPV types differs depending on 
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geographical region with the exception of HPV 16, which is the most common type in 
every region studied (Bosch). It is further estimated that 630 million people worldwide 
are affected by HPV infection of some sort or another (WHO).  
Since HPV 16 and 18 are transmitted almost exclusively via sexual transmission, 
it is unsurprising that the main risk factors for contracting HPV in women include new 
male sexual partners, increased number of lifetime partners, and non-monogamous male 
partners (Chelimo et al., 2012).  A Danish cohort study found that, of the women who 
were not sexually active at the start of the study, 35.4% of those who initiated sexual 
activity before the 2-year follow up were positive for HPV infection (Chelimo et al., 
2012). These results are not insignificant and show that acquisition of new male sexual 
partners is a primary risk factor for HPV infection.  
An increase in the number of lifetime sexual partners is also a major risk factor, as 
demonstrated by a Swedish study, the results from which illustrated that, compared to 
females with only one sexual partner, those with 6-9 partners were five times more likely 
to test positive for HPV and women with 10 or more sexual partners were eleven times 
more likely to test positive for HPV infection (Chelimo et al., 2012).  
Another study conducted by Rositch et al. (2012) showed within a cohort of 885 
women aged 35-60 years, 700 (79%) had incident HPV infection, 85% of which occurred 
in women with no new sexual partners; 72% of the newly found HPV infections in the 
35-60 years cohort were amongst women with five or more lifetime sexual partners. 
Rostich et al. (2012) concluded that these findings are the result of reactivation of a 
previous infection in this age group.  
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Figure 3. Sexual behavior risk factors for acquiring HPV infection. Number of 
lifetime sexual partners appears to put women ages 35-60 years at higher risk for new 
HPV incidence than an increase in new sexual partners (taken from Rositch et al., 2012). 
 
These data suggest that HPV may re-activate later in life in many cases and is attributable 
not just to recent sexual activity, but to lifetime activity (Rositch et al., 2012). 
Male sexual behaviors also have an impact on the prevalence of HPV, indicating 
that men are a reservoir for HPV infection. For example, in the US, a study by Winer et 
al. (2003) showed that women who have non-monogamous male partners have five times 
the incidence of HPV infection than those who had monogamous male partners (Chelimo 
et al., 2012).  
 In order for cervical cancer to develop, one must be have a persistent infection 
with HPV.  The majority of HPV infections are cleared or become dormant without 
treatment; the one-year clearance rate in women is 40-70% overall, 100% in younger 
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women within 2-5 years, and the one-year clearance rate in men is 75% (Erickson et al., 
2013). For the 30-50% of women who do not initially clear their HPV infection, 
approximately 8-28% will develop CIN2/3 (HSIL) and 3-5% will develop ICC (Erickson 
et al., 2013). Co-factors that increase the likelihood of HPV persistence  (see Table 2) 
include an increase in the number of lifetime sexual partners, cigarette smoking, long-
term oral contraceptive use (five or more years), high parity (five or more pregnancies), 
immunosuppression, and co-infection with Chlamydia or Herpes Simplex Virus Type 2 
(HSV-2) (Carter et al., 2011).  
 
Table 2. Behavioral and demographic risk factors for cervical cancer. This table 
shows risk factors for contracting HPV infection (adapted from Aggarwal, 2014) 
Cigarette smoking disrupts the functioning of Langerhans cells, which process antigens in 
the cervix, through by-products of nicotine breakdown which are deposited in the cervix. 
Oral contraceptives enhance gene expression of HPV –related genes and maintains 
mitotic activity in the transformation zone; high parity also does so; immunosuppression, 
such as HIV infection, organ transplant, or autoimmune diseases such as rheumatoid 
 11 
arthritis or lupus, and co-infection with Chlamydia or HSV-2 are associated with 
inflammatory processes that allow genetic instability (Carter et al., 2011). 
Men and HPV- related cancers: genital and non-genital  
 While HPV is most commonly thought of in the context of cervical cancer and 
women’s health, it also has a significant impact on males. Males are at particularly high 
risk for contracting HPV infection themselves; it is estimated that HPV prevalence in 
men may be equivalent, or higher than HPV prevalence in women; recent multinational 
cohort study reported that 50.5% of men tested are positive for at least one type of HPV 
(Giuliano et al., 2008). 
 The carcigenicity of high-risk HPV types are not exclusive to women and HPV 
DNA is prevalent in anal and penile cancers. The incidence of anal cancer is currently on 
the rise and has increased from 0.5/100,000 in 1974 to 1.3/100,000 in 2004 (Giuliano et 
al.). About 85% of anal cancers can be attributed to HPV infection. The highest incidence 
of HPV-associated anal cancer is for men who have sex with men (MSM) (Giuliano et 
al.).  Co-factors for contraction of HPV include being a single male, increase in number 
of lifetime sexual partners, history of anogenital warts, and HIV infection (Giuliano et 
al.).  HPV DNA is also present in 46.9% penile cancers, which account for less than 
0.5% cancers in men; HPV 16 and 18 have the highest incidence (Giuliano et al.). 
 As previously stated, HPV is known to cause and/or be associated with other 
malignancies in addition to cervical cancer, which include anal cancer, penile cancer, and 
head and neck cancers including oropharyngeal cancer, oral cancer, larynx cancer.  
 12 
Oropharyngeal cancers are the sixth most prevalent cancer worldwide, and the thirteenth 
most prevalent in the United States, with HPV 16 prevalence in over 90% of 
oropharyngeal cancers, 69% of laryngeal cancers, and 68% of oral cavity cancers 
(Giuliano et al.). The epidemiology of oropharyngeal cancers has changed over the past 
20 years.  Previously most common in low-income and minority men aged 60 and older 
who smoked or drank heavily. The typical patient with a head and neck malignancy is a 
now a white, college-educated, non-smoker in his forties.   
        Over the past 20 years, rates of smoking and smoking-related cancers in the US have 
decreased, while rates of HPV-related cancers have increased. In 1984 only 23% of 
oropharyngeal cancers contained HPV DNA, while now more than at least 70% of 
incident oropharyngeal cancers are HPV-related (Osazuwa-Peters, 2013). Men are twice 
as likely to be infected than women (Osazuwa-Peters, 2013). There are currently no 
screening tests or protocols to prevent oropharyngeal cancers as there are to prevent 
cervical cancers.  
HPV Vaccines  
 Zur Hausen’s isolation of HPV 16 and 18 in cervical cancers created the 
opportunity for the development of a vaccine that could prevent cervical cancer by 
protecting against infection with high risk HPV types. HPV infections are nonlytic and 
therefore protected from the immune system implicating the need for a vaccine against 
high risk, carcinogenic HPV types. (Markowitz et al., 2012). 
 Currently, two vaccines are available in the United States and have been approved 
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in over 100 countries since their development: Gardasil and Cervarix (Kim, Park, Ko, Yi, 
Cho, 2013). These vaccines are made from virus like particles (VLP), which are 
assembled through recombinant DNA technology (Carter et al., 2011).  The antigenic 
proteins expressed are L1 virus capsid proteins which self assemble into VLP’s and are 
isolated via yeast or viral expression systems (Carter et al., 2011). 
 These vaccines are recommended for administration to females and males before 
sexual debut in developed countries. Gardasil is a quadrivalent vaccine that contains 
VLPs from HPV 6, 11, 16, and 18 and is licensed for females and males 9-26 years of 
age (Markowitz et al., 2012). It is FDA approved to prevent HPV infections associated 
with 70% of ICC’s (HPV 16 and 18) and to prevent HPV infection of types associated 
with >90% of genital warts (HPV 6 and 11). Cervarix is a bivalent vaccine that contains 
L1 VLP’s for HPV 16 and 18 and is licensed for females 9-25 years of age (Markowitz et 
al., 2012). Cervarix was designed to protect against malignant, high-risk HPV infections 
only and has no protective value for genital warts. 
These vaccines are administered in three doses: Gardasil is given  to age-
appropriate females at 0,2, and 6 months and Cervarix is given at 0,1, and 6 months 
(Carter et al., 2011). Although the standard protocol for both vaccines has included a 
three-dose schedule,  recent reports show that antibody titers in response to two doses are 
just as effective as those for three doses (NHS England). Although this research is not yet 
conclusive and is weaker for Gardasil than Cervarix, these findings have led public health 
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officials in the UK to change their school-based vaccination programs from a three-dose 
schedule to a two-dose schedule.  
 Current recommendations by the Advisory Committee for Immunization 
Practices in the US “recommends routine vaccination at age 11 or 12 years with HPV4 
(quadrivalen vaccine Gardasil) or HPV2 (bivalent vaccine Cervarix) for females and with 
HPV 4 for males…vaccination series can be started beginning at age 9 years. HPV 4 and 
HPV 2 are each administered in a 3-dose schedule” (Markowitz et al., 2012). 
Additionally, there are “catch up” programs for females 13-26 and males 13-21 years old 
(Markowitz et al., 2012). 
Clinical trials for vaccine efficacy in females have shown that Gardasil is 98.2 % 
effective against HPV 6,11,16,18 in CIN 2/3 or adenocarcinoma in situ, and Cervarix is 
94.9% effective against HPV 16 and/or 18 in CIN 2/3 and adenocarcinoma in situ 
(Markowitz et al., see Table 3 for more detailed efficacy results). Cervarix has also 
shown cross-protective qualities against carcinogenic HPV types 33, 31, 45, 51 (Erickson 
et al., 2013) 
Efficacy studies in males, though less numerous, have also shown that Gardasil is 
effective in preventing HPV and associated anal and genital lesions. Giuliano et al. 
(2011) conducted an efficacy study amongst 4,065 healthy young males ages 16-26 years, 
showing that Gardasil is 90.4% effective against external genital lesions, 89.4% effective 
against genital warts, and 100% effective in preventing penile intraepithelial neoplasia. 
 15 
These results are similar to those found in HPV vaccine efficacy studies in females, 
providing evidence supporting vaccination of males.   
 
Table 3. Efficacy of quadrivalent HPV vaccine against HPV 16,18,6, and 11, in 
males. This table shows that the quadrivalent HPV vaccine, Gardasil, is nearly as 
effective in males as in females supporting vaccination of adolescent males (taken from 
Giuliano et al., 2011). 
 
 Recently, a nonavalent vaccine was developed which protects against HPV 16, 
18, 6, 11 and five other oncogenic types of HPV: 31, 33, 45, 52, and 58. In an efficacy 
study for this new vaccine, Joura et al. (2015) suggested that, “the 9vHVP vaccine offers 
the potential to increase overall prevention of cervical cancer from approximately 70% to 
approximately 90%.” The results from this study show that the 9vHVP vaccine is 
protective against cancers caused by HPV 31, 33, 45, 52, and 58, and is equally as 
protective against HPV 16, 18, 6, and 11 as Gardasil (Joura et al.,  2015). 
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Vaccine Uptake in the United States  
As of 2013, only 57.3% of females in the United States, ages 13-17 years old, had 
initiated the HPV vaccine (received at least one dose), among which only 37.6% had 
completed the vaccine; 34.6% males ages 13-17 years had initiated the HPV vaccine in 
2013 and 13.8% had completed the recommended three doses (“CDC - Teen Vaccination 
Coverage - NIS – Teen - Vaccines,” n.d.). These statistics are much lower than those 
associated with other vaccines routinely administered to teenagers, including the Tdap 
and meningococcal vaccinations (“National and State Vaccination Coverage Among 
Adolescents Aged 13 Through 17 Years --- United States, 2010,” n.d.).         
 
 
 
 
                  
Figure 4. Estimated vaccine coverage of adolescents 13-17 years of age taken from 
the National Immunization Survey (2006-2010). The initiation and completion of 
HPV vaccination remains significantly below coverage of the Tetanus, diphtheria, 
acellular pertussis vaccine and the meningococcal vaccines, which are given routinely 
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for school-entry requirements. (Taken from the “National and State Vaccination 
Coverage Among Adolescents Aged 13 Through 17 Years --- United States, 2010,” n.d.) 
 
The disparities seen in vaccine uptake are due to many barriers, institutional and 
demographic, suggesting that general vaccination protocols are not sufficiently effective 
in administering HPV vaccines. This calls for implementation of new strategies for 
education about the HPV vaccines and for alternative strategies of vaccine delivery. 
These alternative strategies include offering the vaccine in non-traditional sites such as 
school centers, pharmacies, and community-based clinics (“President’s Cancer Panel 
Issues Urgent Call to Action to Increase HPV Vaccination,” n.d.). 
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PUBLISHED STUDIES  
 
Literature Review 
 To conduct this literature review, I used the PubMed online database to find 
sources that outline barriers to achieving higher HPV vaccination coverage and published 
studies that document the successes and promise of using alternative vaccination sites to 
increase coverage.  I used search terms including “hpv vaccination”,“parents and 
physicians”,“perception”,“mandates”,“adolescents,“school-based programs”, “alternative 
sites”, “vaccination and pharmacies”.  I excluded any articles that focused on specific 
population subsets or underdeveloped nations. After conducting my initial search, I 
decided to focus on school-based vaccination programs and pharmacies as alternative 
vaccination sites.  
  
Barriers to Vaccination Uptake 
 HPV vaccines are unique in that they prevent sexually transmitted infections. 
Holman et al. (2014) examine various barriers to HPV vaccination uptake, specifically 
those concerning healthcare professionals (HCP), parents of adolescents, and underserved 
populations.  
 19 
                            
Table 4. Barriers to HPV vaccine uptake among HCP’s, parents, and underserved 
populations. This table shows barriers to HPV vaccine uptake with regards to HCP’s, 
parents, and the underserved (adapted from Holman et al., 2014). 
 
In each of these categories, they found having insufficient information to be among the 
top three barriers to vaccination uptake. Other cited barriers also stem from having 
inadequate education on HPV and the vaccine, including physicians’ preference for 
vaccinating older females versus younger females and parents’ belief that their daughter 
is too young to be vaccinated, which both demonstrate a lack of knowledge about how 
the HPV vaccine works (Holman et al., 2014) Based on these findings it seems that 
having sufficient understanding of HPV and its vaccines is key to increasing vaccine 
initiation. 
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 Since adolescents cannot provide legal consent for their own vaccination in most 
cases, it is in their best interest that both they and their parents have an understanding of 
the risks associated with HPV and the limitations of the vaccine. For example, it is 
pertinent that adolescents and their parents realize that HPV vaccination is most effective 
before sexual debut and that vaccination does not provide protection from other sexually 
transmitted infections (STI’s) or eliminate the need for cervical cancer screening. 
Hendry, Lewis, Clements, Damery, Wilkinson (2013) conducted a review of girls’ and 
parents’ knowledge gaps in HPV vaccination and found that, while the vaccine is 
generally accepted, knowledge is generally poor:  
“three of the 10 parents who declined the vaccines said they had insufficient information 
with which to make an informed decision…many girls described how an understanding 
of why they were being vaccinated and the benefits of HPV vaccination would help 
reduce their fear”  (Holman et al., 2014) 
 In another study, Hendry et al. (2013) found that parents did not understand why 
their daughters should be vaccinated against an STI at such a young age, and that, for UK 
mothers and some vaccinated females, HPV vaccination was interpreted as a means to 
eliminate the need for cervical cancer screening. This review also illuminated 
misconceptions about risks associated with HPV, particularly that condoms are effective 
in preventing HPV transmission and that the vaccine is protective for STI’s other than 
HPV infection. Hendry et al. (2013) also documented that parents and young girls were 
misinformed in thinking that monogamy affords protection, which shows a general lack 
 21 
of knowledge among parents and young females about risks associated with HPV 
acquisition. 
 Another barrier to vaccination uptake is parent and physician perception of the vaccine. 
Holman et al. (2014) found that, among their healthcare professional participants, the 
number one barrier to offering the vaccine to their patients was “parents’ attitudes and 
concerns regarding HPV vaccination”. Risk compensation, or fear that HPV vaccination 
will encourage females to initiate sexual activity earlier or engage in riskier sexual 
behavior, is among parental concerns that contribute to physicians’ hesitation (Zimet, 
Rosberger, Fisher, Perez, Stupiansky, 2013). 
 
While this concern is understandable, it is unfounded and has been disproven by 
many studies: Liddon, Leichliter, Markowitz (2012) conducted a cross-sectional study in 
the US and found that there was no significant evidence of sexual “disinhibition” among 
vaccinated females when compared to unvaccinated females; vaccinated females were 
actually found to be more likely to always use a condom compared to unvaccinated 
females who were found to use a condom some or non of the time.  
Additionally, Mullins et al. (2012) conducted a study with females 13-21 years 
old who had initiated HPV vaccination. This study found that half of the girls perceived a 
risk of HPV and more than half of the girls felt the need for safer sex practices post-
vaccination, suggesting that HPV vaccination could actually promote safer sex practices.  
Healthcare professionals’ concerns over parental attitudes and perceptions of 
HPV vaccination are extremely detrimental to HPV vaccination uptake in the US. It has 
been shown physician recommendation is key for parents’ and female adolescents’ 
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decision to initiate the HPV vaccine. In another cross-sectional study conducted by 
Liddon, Hood, Leichliter (2012), it was shown that the number two reason for not 
initiating vaccination among females 15-24 years old was lack of provider 
recommendation, second only to no perceived risk.  
 
Table 5. Reasons for not initiating HPV vaccine among girls 15-24 years old (taken 
from Liddon et al., 2012). 
 
Perkins et al. (2014) also explore the impact of physician recommendation and 
influence of timing and delivery of such recommendations on parents’ decision to initiate 
the vaccine. The most common reason parents cited for not vaccinating their adolescent 
was never having been offered the vaccine by their daughters’ provider and “many stated 
they would have accepted the vaccine if offered” (Perkins et al., 2014).  
         Another barrier to vaccination in this study was that physicians presented the 
vaccine as an optional recommendation. Additionally, Perkins et al. (2014) found that 
physicians often delay vaccination for their patients because they anticipate that parents 
will think their children are too young for sexual activity or because they themselves 
profile the adolescents as being too young or not at risk for HPV acquisition.  
One physician interviewed in this qualitative study said, “We know that if you 
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don’t get a vaccine the first time you mention it, the chances of getting kept up to date are 
considerably less over time.”  After interviewing physicians from both public clinics and 
private practices, Perkins et al. (2014) found that some strategies for successfully 
recommending uptake include co-administration of the vaccine with other routine 
adolescent vaccinations, emphasis on cancer prevention, and giving strong 
recommendations without the option to say no.  
Although some of this literature reviewed showed a general lack of knowledge 
regarding HPV infection and vaccination, an international comparison conducted by 
Marlow, Zimet, McCaffery, Ostini, Waller (2013) showed that, while vaccine uptake in 
the US lags far behind Australia and the UK, women and men in the US actually have a 
better general knowledge of HPV (see Table). Being male and/or having less education 
were associated with having less knowledge about HPV and its vaccination across all 
three countries; male awareness was higher in the US with 63.6% male awareness of 
HPV in the US versus 39.2% in the UK and 41.4% in Australia (Marlow et al., 2013) In 
general, females tend to be more aware of HPV and the HPV vaccine.  
    
Table 6. A comparison of general knowledge about HPV and the HPV vaccine 
among men and women in the US, UK, and Australia (taken from Marlow et al., 
2013). 
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This study showed that having awareness of HPV does not necessarily coordinate with 
vaccine uptake or a complete understanding of HPV and consequences of HPV infection. 
Among those who had heard of HPV, there were large knowledge gaps. As shown in 
Table , more than half of those who had heard of HPV did not know it can cause genital 
warts or that most sexually active people will contract HPV at some point (Marlow et al., 
2013). Additionally, those who were familiar with the HPV vaccine did not know it is 
given in three doses or that its administration is optimal before sexual debut (Marlow et 
al., 2013). These trends were seen across all three examined countries.  
 
 
Table 7. An expanded list of knowledge points from an international comparison of 
HPV and HPV vaccine awareness among men and women in the US, UK, and 
Australia (taken from Marlow et al., 2012). 
 
 The vaccine coverage in Australia and the UK is more than twice that of that in 
the US. The results of this study suggest that knowledge gaps are not the primary barrier 
to increasing HPV vaccination uptake. The ultimate difference between the US and the 
other countries studied here is that the UK and Australia both have national school-based 
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vaccination programs whereas the US still relies primarily on administering the HPV 
vaccine in primary care settings. This study is key to emphasizing the need for alternative 
vaccination strategies in the US.  
 Another reason to explore alternative strategies for vaccine delivery is that most 
adolescents in the US do not regularly visit their primary care provider (if they have one) 
for preventive care services. Rand et al. (2007) conducted a study to demonstrate and 
categorize adolescent healthcare visits which showed that 1/6-1/3 adolescents do not see 
their physician annually and that only 9.1% of total outpatient visits in the US from 1994-
2003 were adolescent visits (see Figure 5) (Rand et al., 2007). This study also recorded 
the ratio of preventive care visits to acute visits showing that only 9% of adolescent visits 
are preventive. This group of researchers determined visits by gender and stage of 
adolescence (early v. late). They show that females have more preventive visits than 
males and that early adolescents (11-14 years old) had three times more visits than late 
adolescents.  
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Figure 5. Adolescent healthcare visits from 1994-2003. This graph shows male and 
female adolescent healthcare visits categorized by the nature of the visit: preventive or 
other (taken from Rand et al., 2007). 
 
Adolescent vaccines that are given during preventive visits include 80% MMR, 70% 
Hepatitis B, and 64% Tdap vaccines (Rand et al., 2007). Since HPV vaccine requires 
three separate doses and thus repeat visits, this system does not bode well for achieving 
high HPV vaccine coverage.  
 
Why not just mandate HPV Vaccination?  
 The United States has required vaccination for public school entry since the early 
1800’s. The Tdap (tetanus, diphtheria and acellular pertussis). polio, measles, and 
Hepatitis B (HepB) vaccines are among mandated vaccines in most states (Javitt, 
Berkowitz, and Gostin, 2008).  
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There are several reasons that suggest a mandate for HPV vaccination is pre-
emptive and radical. HPV is not transmitted through casual contact or fatal in childhood. 
Therefore,  “HPV does not threaten an imminent and significant risk to the health of 
others. Mandating HPV would therefore constitute an expansion of the state’s authority 
to interfere with individual and parental autonomy” (Javitt et al., 2008).   
Currently, 41 states have legislation for HPV vaccination but only two states have 
HPV vaccine mandates: Virginia and the District of Columbia (DC). In Virginia, girls 
must receive three doses on the exact dosing schedule recommended by the Advisory 
Committee on Immunization Practices (ACIP) before the sixth grade with an option for 
parents to opt-out (Javitt et al., 2008). DC requires that parents report vaccine completion 
upon their daughter’s entrance to sixth grade under the Vaccination and Reporting Act of 
2007 and requires annual reporting from the Department of Health (Javitt et al. 2008). 
The opt-out clauses for these mandates are liberal and have resulted in less than 50% 
coverage in Virginia and DC (“National and State Vaccination Coverage Among 
Adolescents Aged 13 Through 17 Years --- United States, 2010,” n.d.). Rhode Island has 
issued a mandate for HPV vaccination that will go into effect in August 2015. This 
mandate is unique in that there are no exemptions: all students entering seventh grade 
must initiate the vaccine (by August 2015) all students entering eighth grade must have at 
least two doses (by August 2016) and all students entering ninth grade must have 
completed all three doses (by August 2017) (North, n.d.). While this mandate is 
revolutionary, Rhode Island already has over 80% coverage of the HPV vaccine. 
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ACIP recommendations must constitute a “public health necessity” and fit into a 
“reasonable relationship” principle outlined in Jacobsen v. Massachusetts, the first 
vaccine mandate case in American history, through which smallpox vaccine was 
mandated for school attendance. Other mandated vaccines prevent diseases that  are 
highly contagious and associated with high short-term morbidity and mortality. As such, 
all children attending school have an equivalent risk of acquiring the disease, showing a 
clear relationship of attending school and contracting the disease which provides support 
for public school vaccination mandates (Javitt et al., 2008). 
 Javitt et al. (2008) point out that, since HPV is not an equal risk to all children 
(i.e. all children are not sexually active) and HPV is not immediately fatal or morbid, it is 
difficult to say that it fits into the principles outlined in Jacobsen v. Massachusetts which 
have allowed other vaccines to be mandated for school attendance.  
Alternative settings for vaccination 
 Traditional vaccination settings in the US are essentially limited to primary care 
facilities. While this makes childhood vaccination feasible because infants and young 
children have many well visits and thus, more opportunities for vaccination, it leaves 
adolescents at a disadvantage because they have very few primary care visits, as 
documented previously by Rand et al. (2007). This creates a hurdle for all adolescent 
vaccines, but especially so for the HPV vaccine because it requires three visits. Primary 
care settings are particularly ineffective for vaccine delivery to males, who have 
significantly fewer physician visits a year than females throughout adolescence.  
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According to Shah, Gilkey, Pepper, Gottlieb, and Brewer (2014), “healthcare 
provider recommendation is by far the strongest predictor of HPV vaccine.” 
Unfortunately, almost half of US adolescents ages 12-17 do not have access to a primary 
care provider (Strickland, Jones, Ghandour, Kogan, and Newacheck, 2011). This statistic 
compounded with evidence that providers lack knowledge about the HPV vaccine, and 
are often hesitant to recommend the vaccine to the targeted age groups (ages 11-12) 
suggests that alternative sites should be explored. 
 Potential alternative vaccination settings include, but are not limited to, 
pharmacies, school-based health centers, mass vaccination in schools, OBGYN clinics, 
STI clinics, family planning clinics, emergency departments, and dental practices (Shah 
et al., 2014). Shah et al. (2014) define the reach, acceptability, and feasibility of each of 
these potential sites in their comprehensive review of potential alternative vaccination 
settings for adolescents. Table 8 indicates that pharmacies, school heath centers, and 
mass vaccination in schools show the most promise as alternative sites.  
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Table 8. Alternative vaccination venues. This table shows the strength of evidence 
found for non-traditional vaccination sites including pharmacies, school health centers, 
mass vaccination in schools, OBGYN clinics, STI clinics, family planning clinics, 
emergency departments and dental offices. Each venue is evaluated on reach, 
acceptability, and feasibility (taken from Shah et al., 2014). 
 
 In their discussion of pharmacies as alternative sites, Shah et al. (2014) point out 
that, with 250 million pharmacy visits per week, pharmacies have the potential to reach a 
large portion of eligible adolescents, especially in vulnerable urban and rural populations 
where adolescents are less likely to have access to preventive care. Modern pharmacists 
are actually trained as immunizers for children and adults (Romanelli and Freeman, 
2012), lending further support to pharmacies as trustworthy and legitimate alternative 
vaccination sites. With regards to cost and insurance concerns, Shah et al.  (2014) cite a 
study from a cohort of California pharmacies in which it was proven that vaccination at 
pharmacies is cheaper per unit than in primary care facilities. Additionally, pharmacies 
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circumvent office visit costs and can directly bill patients’ insurance companies, unlike 
many other alternative sites (Shah et al., 2014).  
 The alternative site for which there is strongest evidence of reach, acceptability, 
and feasibility is the school-based health center. School health centers are “clinics that 
provide students, and sometimes other family members, with comprehensive medical 
care, including primary care, mental health and nutrition counseling services” (Lofink et 
al., 2013). While these centers exist in only 6% of US schools, 85% can provide vaccines 
and 80% stock the HPV vaccine in particular; they are also likely to service high-risk 
adolescents who are low income, uninsured, or minority students (Shah et al., 2014).  
Schools that do have school-based health centers have the potential to reach all 
adolescents who attend that school and to complete the vaccination for these students 
since parents do not have to take time off to attend a physician visit.  
 Mass vaccination in schools is another viable option and has proven to be 
extremely successful in other Western countries including Australia, the UK, and Canada. 
Mass school-based vaccination programs have the potential reach most adolescents 
because most adolescents in the US attend school (Shah et al. 2014). The only 
shortcomings pertain to funding issues, and lack of partnerships with necessary providers.  
 Overall, Shah et al. (2014) show that pharmacies and mass vaccination in schools 
are the best options for alternative settings in order to increase HPV vaccination 
coverage. 
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School-based vaccination programs 
 HPV vaccine coverage in the US is achieved mostly through primary care settings 
and, coincidentally, lags far behind its peer countries. In 2007, the coverage with one 
dose in the US was 25% (Markowitz et al. 2012). This statistic increased to 57.3% in 
2013 (“CDC - Teen Vaccination Coverage - NIS – Teen - Vaccines,” n.d.). Canada, on 
the other hand, requires that all provinces have school-based vaccination programs for 
girls in at least one grade between 4 through 8 and offers the vaccine for free to girls 
throughout the provinces; this system achieved 80-85% coverage in eastern Canadian 
provinces in its first year alone (Markowitz et al., 2012).  
 Australia implemented a publically funded school-based vaccination program in 
2007, vaccinating females 12-13 years old with an additional two-year catch-up program 
for girls 13-17 years of age; this has achieved 70% coverage across Australia (Markowitz 
et al., 2012).  
 In Europe, 22 countries added HPV vaccine to their respective immunization 
programs by 2012 (Markowitz et al., 2012). The majority of these programs were primary 
care programs while some countries have chosen the school-based approach. The UK is 
notable for it’s publicly-funded school-based program which targets 12-13 year-old girls 
with a catch-up for girls up to 18 years of age launched in 2008 which achieved 74% 
coverage by 2010 (Markowitz et al., 2012). This is twice the vaccine coverage in the US 
for 2010, suggesting the US could benefit tremendously from implementing a school-
based vaccination program for adolescents.  
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 Australia was one of the first countries to launch a government funded, school-
based HPV vaccination program in 2006. This program aims to vaccinate 12-13 year old 
girls with a catch-up for girls up to 17 years of age in schools and for women up to age 26 
in primary care settings; 2013, the Australian program expanded to include boys 12-13 
years of age with a catch-up for boys 14-15 years old (Brotherton et al., 2013).  The 
program relies on partnerships between health departments, nurses, general practitioners 
and schools and is coordinated primarily by individual state health departments. The 
health departments are in charge of purchasing and distributing the vaccines to schools as 
well as formulating consent forms, educational information and vaccine protocols. 
Individual schools coordinated vaccination within the schools and used their own school-
based personnel including nurses and some general practitioners (Brotherton et al., 2013).   
 Table 9 shows data taken from the National HPV Vaccination Program Register 
(NHPVPR) in Australia from 2011. After four years of school-based vaccination, 70% of 
females 12-17 years old completed the HPV vaccine (Brotherton et al., 2013). This is 
more than twice US vaccination was in 2011 lending strong support for a school-based 
approach to HPV vaccination distribution.  
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Table 9.  2011 HPV vaccine coverage in Australia, by province and state. This table 
shows the HPV coverage statistics for states in Australia as a result of its national school-
based HPV vaccination program launch in 2007 (taken from Brotherton et al., 2013). 
 
Brotherton et al. (2013) even found data on vaccine coverage for high-risk girls who 
identified as Aboriginal or Torres Strait Islander; the three-dose completion for this group 
of girls was 64% which is still twice that of the US. 
 The impressive vaccination coverage statistics from Australia’s school-based 
program are further supported by follow-up studies that have shown a significant 
decrease in genital HPV prevalence and cervical abnormalities within five years of its 
inception. Osborne et al. (2015) recruited 431 women 18-25 years old in Victoria, 
Australia via social media. These women self-collected vaginal swabs which were tested 
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for HPV DNA (results shown in Figure 6). This group found a 1.6% prevalence of HPV 
16, the most prevalent high-risk HPV type seen worldwide, and no prevalence of the 
remaining three vaccine-targeted types (HPV 6,11, or 18).   
 
 
Figure 6. HPV prevalence, by genotype, in women ages 18-25 years in Victoria, 
Australia in 2012. This figure shows the respective prevalence of different types of HPV 
in women ages 18-25 years from Victoria, Australia. Samples were self-collected vaginal 
swabs (taken from Osborne et al., 2013). 
 
This is a significant decrease from reported HPV 16 prevalence in Victoria before the 
nationwide vaccination program, which was found to be approximately 18% by Garland, 
Skinner, and Brotherton (2011).  
 In addition to the findings by Osborne et al. (2015), a 2011 cross-sectional study 
of Australian women ages 18-24 years that compared HPV prevalence to pre-vaccination 
prevalence from 2007, showed a 77% decrease in HPV 16 prevalence with a significant 
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reduction in the prevalence of other vaccine targeted HPV types (Tabrizi et al., 2012). 
The fall in HPV prevalence correlates closely with pre-vaccination cost-effect predictions 
made by Smith and Canfell (2014), which projected a 64-79% decrease in HPV 
prevalence and lent support for the $580 million nationwide program rolled out in 2007 
(Smith and Canfell, 2014).  
Australia has also seen a significant decrease in genital warts prevalence caused 
by HPV 6/11: Read et al., (2011) found a 90% decrease in genital warts prevalence in 
males and females less than 21 years of age.  
Another study by Tabrizi et al., (2014) confirmed a reduction in vaccine-targeted 
HPV types among young women and a reduction in unvaccinated women suggesting that 
implementing national HPV vaccination programs could confer herd immunity.  
 
Pharmacies as an alternative vaccination site 
 As shown by Shah et al. (2014), pharmacies are a promising non-traditional site 
for administering adolescent vaccinations, HPV in particular. Pharmacies are unique in 
that they are highly accessible and convenient, have extended hours of operation, and can 
file insurance claims on site.  
 In 1994, the Department of Health and Human Services recommended that 
pharmacists be included in the provision of population-based vaccinations, most notably 
the influenza vaccine, and, in 1996, the American Pharmacists Association began training 
pharmacists on immunization programs and best practices (Schaffer et al., 2008). 
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Pharmacists routinely provide influenza, pneumococcal, hepatitis, and Tdap vaccines to 
children and adults (Schaffer et al., 2008). 
 One of the most attractive features of pharmacies as alternative vaccination sites 
is that they offer extended hours that one cannot find in most primary care clinics. Goad, 
Taitel, Fensterheim and Cannon (2013) conducted a study to assess the proportion and 
types of vaccines that were administered during off-hours (i.e. hours outside the 9AM -
5PM, Monday-Friday work schedule) at Walgreens pharmacy stores across the US 
Of the 6.25 million vaccines delivered at Walgreens pharmacies in 2011, they 
found that 30.5% were given during non-traditional hours. HPV vaccine was the third 
most common vaccine administered during the examined hours which accounted for 
33.8% of the total HPV vaccines provided through Walgreens in 2011 (see Figure 7). 
Additionally, Goad et al. (2013) found that patients under the age of 18 were vaccinated 
off-hours in greater proportions than any other age groups studied.    
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Figure 7. Most frequently administered vaccines during off-hour visits at Walgreens 
pharmacy locations in 2012. This figure shows the vaccines delivered in the greatest 
numbers at Walgreen’s pharmacies during off-hours of which HPV is the third most 
common (taken from Goad et al., 2013).  
While results from Goad et al. (2013) indicate that pharmacies are a promising and 
convenient alternative HPV vaccination site, it is not entirely feasible nationwide.  
In recent years, most states have adopted legislation allowing pharmacists to 
deliver the HPV vaccination, however, these laws vary in the autonomy they afford 
pharmacists: 80% of states in the US allow pharmacists to administer the HPV vaccine to 
women 19 years and older, 61% of states allow pharmacists to provide the vaccine to 
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girls age 12 years and older, and 59% to girls 9 years and older (Brewer, Chung, Baker, 
Rothholz, and Smith, 2014). 
 Figure 8 shows a tiered system developed by Brewer et al. (2014) that categorizes 
state legislation for HPV vaccine administration: Tier 1 states allow pharmacists the most 
freedom and will let them provide the HPV vaccination without a prescription from a 
physician; Tier 2 states allow pharmacists to administer the vaccine after signing a 
supervision agreement with a prescriber which allows her to provide the vaccine 
irrespective of their primary care doctor; Tier 3 states afford similar privileges but only to 
patients of the signing prescriber; Tier 4 states allow provision of the vaccine with a 
prescription given by a primary care provider and Tier 5 states do not allow HPV vaccine 
provision by pharmacists 
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Figure 8.  Pharmacist HPV vaccination administration privileges by state. This 
figure shows a visual representation of pharmacist vaccination privilege in the US as it 
pertains to HPV vaccines (taken from Brewer et al., 2014). 
 
 
The ten states that do not allow pharmacists to provide the HPV vaccine include: Maine, 
Ohio, Florida, West Virginia, Massachusetts, New Hampshire, Connecticut, New York, 
Maryland, and North Carolina; half of these states have pending legislation to afford 
pharmacists the privilege to vaccinate adolescents against HPV (Brewer et al., 2014).  
 The biggest barriers to extending pharmacists’ HPV vaccine provision rights, as 
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documented by Brewer  et al. (2014), concern protecting “the medical home”. The 
American Academy of Pediatrics (AAP) defines the medical home as “a primary care 
setting that is accessible, continuous, comprehensive, family centered, coordinated, 
compassionate and culturally effective…concerns regarding retail clinics include the 
potential for lack of access to a complete medical history, fragmentation of care, and the 
loss of an opportunity to screen for illnesses or to provide support and follow-up for 
chronic conditions or family issues” (Brewer  et al., 2014). Conflicting views were found 
in a 2012 national study by Kempe et al. (2012) which found that 78% of pediatricians 
support vaccination in alternative settings for children 5-18 years old.  
 Another imminent barrier to using pharmacies as an alternative HPV vaccination 
site is that pharmacies do not accept public health insurance including Medicaid which 
could prevent high-risk, low-income adolescents from receiving HPV vaccination in 
pharmacies. 
 In an interview concerning pharmacists’ views on adolescent vaccine provision in 
pharmacies (Table 10), Skiles, Cai, English, and Ford (2011) found that, while over half 
the pharmacists interviewed believe that HPV vaccine is extremely important, the vast 
majority of them believe that the ACIP recommendations for HPV vaccination are 
controversial because has been viewed as a vaccine against an STI. Participating 
pharmacists also voiced financial concerns with regards to receiving insurance 
reimbursements (Skiles et al., 2011). 
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Table 10.  North Carolina pharmacists’ views on providing adolescent vaccines in 
pharmacies (taken from Skiles et al., 2011). 
 
 Richman, Swanson, Branham and Partridge (2013) created a survey to assess 
North Carolina pharmacists’ stand on legislation to allow pharmacists to administer the 
HPV vaccine. This study showed that pharmacists believe they have more knowledge 
about HPV than the HPV vaccines, however, 70% of the 1600 pharmacists evaluated said 
they would be interested in receiving more education about HPV vaccination (Richman et 
al., 2013). Over half of the surveyed participants indicated that they would be 
comfortable administering the vaccine; the top reported concerns for administering the 
HPV vaccine include: time constraints, insurance companies failing to reimburse, and 
keeping up with 3 required doses. Overall, 64% of survey participants support legislation 
to allow pharmacists to provide the HPV vaccine to adolescents (Richman et al., 2013). It 
was noted that younger pharmacists were more supportive than older pharmacists.  
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DISCUSSION 
 Human papillomavirus is implicated in over 70% of invasive cervical carcinomas 
and 90% of genital warts cases. Cervical cancer is the third most common cancer in 
women worldwide and, because of large strides made in preventive care, the twelfth 
leading cause of death among women in the United States. Additional research has shown 
that HPV not only affects women with respect to cervical cancer but is also implicated in 
oropharyngeal, anal, and penile cancers in men.  
Since 2007, two vaccines to prevent HPV have been available: Gardasil, a 
quadrivalent vaccine protecting against the four most common high-risk types of HPV: 
16, 18, 6, and 11, and Cervarix, a bivalent vaccine for HPV 16 and 18.  These vaccines 
are recommended for girls and boys ages 9-26 years; the proven efficacy for these 
vaccines is over 90% for both sexes.  
Despite the proven efficacy and safety of these vaccines and multiple national 
advertising campaigns for their promotion, HPV vaccine uptake in the US is still only at 
37.6% for females and 13.8% for males (“CDC - Teen Vaccination Coverage - NIS – 
Teen - Vaccines,” n.d.). , which is far less than many of its peer countries. Physician 
recommendation is one of the key factors in parents’ and adolescents’ decisions to initiate 
the vaccine, however, studies have illuminated that some physicians are reluctant to 
recommend a vaccine for a sexually transmitted infection to females prior to sexual 
debut, even though it is proven that the vaccine(s) is most effective pre-sexual debut.  
Currently, the HPV vaccine is being administered in the US through traditional 
vaccination settings (i.e. primary care facilities). Rand et al., 2007 showed that most 
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adolescents do not regularly visit their primary care providers, if they even have access to 
primary care. Given the risks associated with HPV infection, some states have argued 
that HPV vaccines should be mandatory for school attendance but it is difficult to justify 
vaccine mandates, especially for a vaccine protecting against a disease that is transmitted 
almost exclusively via sexual contact (Javitt et al., 2008). Currently only three states have 
mandates for HPV vaccines: Virginia, DC (Javitt et al., 2008) and Rhode Island (North, 
n.d.). These data combined with low uptake of the vaccine in the US suggest that we need 
to explore different methods of vaccine provision for adolescents.  
Shah et al. (2014) found that mass vaccination in schools, school health centers, 
and pharmacies have the greatest potential as alternative sites for adolescent vaccination. 
Given the limited number of school-based health centers in the country (only 6% of 
schools in the US have such centers), I limited this paper to include only mass 
vaccination and pharmacy provision of HPV vaccines.  
There is strong evidence from other Western countries, Australia in particular, 
that mass vaccination in schools is extremely effective for increasing HPV vaccine 
uptake: the national uptake in Australia is now 70%, twice that of the US. The UK and 
Canada have seen similar results from their respective school-based vaccination 
programs. In addition to achieving high vaccine coverage, Australia has also seen a 
substantial decline in HPV 16/18 prevalence and genital warts cases nationwide, 
providing further support for HPV vaccination. 
Pharmacies have also been discussed as good alternative sites for adolescent 
vaccination. I did not find any studies specific to using pharmacies as an alternative site 
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for adolescent vaccination, but I did find evidence indicating that pharmacists are 
interested in providing the vaccine and feel that it is important. Studies also show that 
pharmacy vaccination programs are successful and that the extended hours offered at 
pharmacies allow them to reach a greater patient population. Unfortunately, most states 
do not allow pharmacists much autonomy in providing the HPV vaccines and most 
require pharmacists to have written approval from primary care providers.  
Both pharmacy and school-based vaccination programs have great potential to  
increase HPV vaccine uptake in young men and women throughout the US. Both of these 
proposed sites are easily accessible to most adolescents and have the potential to reach 
those who are the most vulnerable to HPV infection including adolescents from urban or 
rural areas, those from low-income families, and those who are uninsured.  
To increase vaccine uptake in the US, it may be necessary to utilize non-
traditional vaccination venues. Based on the research presented in this paper, mass 
vaccination in schools with an opt-out option for parents is likely the best option that will 
reach the most adolescents. This will require cooperation from and collaboration between 
school personnel, policy makers, nurses, general practitioners, and students.  
Pharmacies are underused as preventive care resources and have enormous 
potential to aid in increasing HPV vaccine uptake because of the convenience they afford 
and the trust put in pharmacists as healthcare providers. In order to harness their 
potential, it is necessary to encourage legislation that will extend HPV vaccination 
privileges to pharmacists and to establish pilot programs. A well-advertised and 
successful pharmacy-based HPV vaccination program could encourage states to pass 
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legislation giving pharmacists greater vaccination privileges and has the potential to 
afford protection against HPV to many at-risk adolescents. However, there would need to 
be checks and balances to ensure that both privately insured and low-income/under or 
uninsured adolescents are vaccinated. Additionally, steps must be taken to guarantee that 
there is sufficient communication between pharmacists and primary care providers. This 
will aid in alleviating physicians’ reservations with regards to using pharmacies for 
preventive care.  
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